Is cholesteryl ester transfer protein inhibition an effective strategy to reduce cardiovascular risk?: CETP as a target to lower CVD risk: Suspension of disbelief?

Circulation

Volumn 132, Issue 5, 2015, Pages 433-440

  Hovingh, G Kees ^a   Ray, Kausik K ^b   Boekholdt, S Matthijs ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANACETRAPIB; CHOLESTEROL ESTER TRANSFER PROTEIN; CHOLESTEROL ESTER TRANSFER PROTEIN INHIBITOR; DALCETRAPIB; EVACETRAPIB; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TA 8995; TORCETRAPIB; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; BENZODIAZEPINE DERIVATIVE; CETP PROTEIN, HUMAN; HYPOCHOLESTEROLEMIC AGENT; OXAZOLIDINONE DERIVATIVE; QUINOLINE DERIVATIVE; THIOL DERIVATIVE;

ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; DRUG EFFICACY; HIGH RISK POPULATION; HUMAN; NONHUMAN; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK REDUCTION; TREATMENT OUTCOME; ANIMAL; ANTAGONISTS AND INHIBITORS; CARDIOVASCULAR DISEASES; DEFICIENCY; DISEASE MODEL; DISORDERS OF LIPID AND LIPOPROTEIN METABOLISM; GENETICS; MOUSE; PATHOPHYSIOLOGY; PHYSIOLOGY; RABBIT; RISK FACTOR;

ANIMALS; ANTICHOLESTEREMIC AGENTS; BENZODIAZEPINES; CARDIOVASCULAR DISEASES; CHOLESTEROL ESTER TRANSFER PROTEINS; DISEASE MODELS, ANIMAL; HUMANS; LIPID METABOLISM, INBORN ERRORS; MICE; OXAZOLIDINONES; QUINOLINES; RABBITS; RISK FACTORS; SULFHYDRYL COMPOUNDS; TREATMENT OUTCOME;

EID: 84939505510     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.115.014026     Document Type: Article

References (51)

1. Brown ML, Inazu A, Hesler CB, Agellon LB, Mann C, Whitlock ME, Marcel YL, Milne RW, Koizumi J, Mabuchi H, Molecular basis of lipid transfer protein deficiency in a family with increased high-density lipoproteins. Nature 1989 342 448 451. doi: 10.1038/342448a0
2. Inazu A, Brown ML, Hesler CB, Agellon LB, Koizumi J, Takata K, Maruhama Y, Mabuchi H, Tall AR, Increased high-density lipoprotein levels caused by a common cholesteryl-ester transfer protein gene mutation. N Engl J Med 1990 323 1234 1238. doi: 10.1056/NEJM199011013231803
3. Briel M, Ferreira-Gonzalez I, You JJ, Karanicolas PJ, Akl EA, Wu P, Blechacz B, Bassler D, Wei X, Sharman A, Whitt I, Alves da Silva S, Khalid Z, Nordmann AJ, Zhou Q, Walter SD, Vale N, Bhatnagar N, O'Regan C, Mills EJ, Bucher HC, Montori VM, Guyatt GH, Association between change in high density lipoprotein cholesterol and cardiovascular disease morbidity and mortality: systematic review and meta-regression analysis. BMJ 2009 338 b92
4. Rader DJ, Hovingh GK, HDL and cardiovascular disease. Lancet 2014 384 618 625. doi: 10.1016/S0140-6736(14)61217-4
5. Fielding CJ, Havel RJ, Cholesteryl ester transfer protein: friend or foe? J Clin Invest 1996 97 2687 2688. doi: 10.1172/JCI118719
6. Barter PJ, Nicholls SJ, Kastelein JJP, Rye K-A, Is cholesteryl ester transfer protein inhibition an effective strategy to reduce cardiovascular risk? The pro case: response to Hovingh et al on p 432. Circulation 2015 132 423 432
7. Tall AR, Plasma cholesteryl ester transfer protein. J Lipid Res 1993 34 1255 1274
8. Fielding CJ, Fielding PE, Molecular physiology of reverse cholesterol transport. J Lipid Res 1995 36 211 228
9. Villard EF, El Khoury P, Duchene E, Bonnefont-Rousselot D, Clement K, Bruckert E, Bittar R, Le Goff W, Guerin M, Elevated CETP activity improves plasma cholesterol efflux capacity from human macrophages in women. Arterioscler Thromb Vasc Biol 2012 32 2341 2349. doi: 10.1161/ATVBAHA.112.252841
10. Scharnagl H, Heuschneider C, Sailer S, Kleber ME, März W, Ritsch A, Decreased cholesterol efflux capacity in patients with low cholesteryl ester transfer protein plasma levels. Eur J Clin Invest 2014 44 395 401. doi: 10.1111/eci.12248
11. Ha YC, Barter PJ, Differences in plasma cholesteryl ester transfer activity in sixteen vertebrate species. Comp Biochem Physiol B 1982 71 265 269
12. Plump AS, Masucci-Magoulas L, Bruce C, Bisgaier CL, Breslow JL, Tall AR, Increased atherosclerosis in ApoE and LDL receptor gene knock-out mice as a result of human cholesteryl ester transfer protein transgene expression. Arterioscler Thromb Vasc Biol 1999 19 1105 1110
13. Marotti KR, Castle CK, Boyle TP, Lin AH, Murray RW, Melchior GW, Severe atherosclerosis in transgenic mice expressing simian cholesteryl ester transfer protein. Nature 1993 364 73 75. doi: 10.1038/364073a0
14. Hayek T, Masucci-Magoulas L, Jiang X, Walsh A, Rubin E, Breslow JL, Tall AR, Decreased early atherosclerotic lesions in hypertriglyceridemic mice expressing cholesteryl ester transfer protein transgene. J Clin Invest 1995 96 2071 2074. doi: 10.1172/JCI118255
15. Föger B, Chase M, Amar MJ, Vaisman BL, Shamburek RD, Paigen B, Fruchart-Najib J, Paiz JA, Koch CA, Hoyt RF, Brewer HB Jr, Santamarina-Fojo S, Cholesteryl ester transfer protein corrects dysfunctional high density lipoproteins and reduces aortic atherosclerosis in lecithin cholesterol acyltransferase transgenic mice. J Biol Chem 1999 274 36912 36920
16. Okamoto H, Yonemori F, Wakitani K, Minowa T, Maeda K, Shinkai H, A cholesteryl ester transfer protein inhibitor attenuates atherosclerosis in rabbits. Nature 2000 406 203 207. doi: 10.1038/35018119
17. Morehouse LA, Sugarman ED, Bourassa PA, Sand TM, Zimetti F, Gao F, Rothblat GH, Milici AJ, Inhibition of CETP activity by torcetrapib reduces susceptibility to diet-induced atherosclerosis in New Zealand White rabbits. J Lipid Res 2007 48 1263 1272. doi: 10.1194/jlr.M600332-JLR200
18. Zhong S, Sharp DS, Grove JS, Bruce C, Yano K, Curb JD, Tall AR, Increased coronary heart disease in Japanese-American men with mutation in the cholesteryl ester transfer protein gene despite increased HDL levels. J Clin Invest 1996 97 2917 2923. doi: 10.1172/JCI118751
19. Hirano K, Yamashita S, Kuga Y, Sakai N, Nozaki S, Kihara S, Arai T, Yanagi K, Takami S, Menju M, Atherosclerotic disease in marked hyperalphalipoproteinemia: combined reduction of cholesteryl ester transfer protein and hepatic triglyceride lipase. Arterioscler Thromb Vasc Biol 1995 15 1849 1856
20. Curb JD, Abbott RD, Rodriguez BL, Masaki K, Chen R, Sharp DS, Tall AR, A prospective study of HDL-C and cholesteryl ester transfer protein gene mutations and the risk of coronary heart disease in the elderly. J Lipid Res 2004 45 948 953. doi: 10.1194/jlr.M300520-JLR200
21. Okamura T, Sekikawa A, Kadowaki T, El-Saed A, Abbott RD, Curb JD, Edmundowicz D, Nakamura Y, Murata K, Kashiwagi A, Sutton-Tyrrell K, Evans RW, Zmuda JM, Maegawa H, Hozawa A, Mitsunami K, Nishio Y, Miljkovic-Gacic I, Horie M, Miyamatsu N, Murakami Y, Kuller LH, Ueshima H, Cholesteryl ester transfer protein, coronary calcium, and intima-media thickness of the carotid artery in middle-Age Japanese men. Am J Cardiol 2009 104 818 822. doi: 10.1016/j.amjcard.2009.05.021
22. Borggreve SE, Hillege HL, Wolffenbuttel BH, de Jong PE, Zuurman MW, van der Steege G, van Tol A, Dullaart RP, PREVEND Study Group An increased coronary risk is paradoxically associated with common cholesteryl ester transfer protein gene variations that relate to higher high-density lipoprotein cholesterol: a population-based study. J Clin Endocrinol Metab 2006 91 3382 3388. doi: 10.1210/jc.2005-2322
23. Borggreve SE, de Vries R, Dallinga-Thie GM, Wolffenbuttel BH, Groen AK, van Tol A, Dullaart RP, The ability of plasma to stimulate fibroblast cholesterol efflux is associated with the-629C->A cholesteryl ester transfer protein promoter polymorphism: role of lecithin: cholesterol acyltransferase activity. Biochim Biophys Acta 2008 1781 10 15. doi: 10.1016/j.bbalip.2007.10.010
24. Thompson A, Di Angelantonio E, Sarwar N, Erqou S, Saleheen D, Dullaart RP, Keavney B, Ye Z, Danesh J, Association of cholesteryl ester transfer protein genotypes with CETP mass and activity, lipid levels, and coronary risk. JAMA 2008 299 2777 2788. doi: 10.1001/jama.299.23.2777
25. Li YY, Wu XY, Xu J, Qian Y, Zhou CW, Wang B, Apo A5-1131T/C, FgB-455G/A,-148C/T, and CETP TaqIB gene polymorphisms and coronary artery disease in the Chinese population: a meta-Analysis of 15,055 subjects. Mol Biol Rep 2013 40 1997 2014. doi: 10.1007/s11033-012-2257-9
26. Ritsch A, Auer B, Föger B, Schwarz S, Patsch JR, Polyclonal antibody-based immunoradiometric assay for quantification of cholesteryl ester transfer protein. J Lipid Res 1993 34 673 679
27. Boekholdt SM, Kuivenhoven JA, Wareham NJ, Peters RJ, Jukema JW, Luben R, Bingham SA, Day NE, Kastelein JJ, Khaw KT, Plasma levels of cholesteryl ester transfer protein and the risk of future coronary artery disease in apparently healthy men and women: the prospective EPIC (European Prospective Investigation into Cancer and Nutrition)-Norfolk population study. Circulation 2004 110 1418 1423. doi: 10.1161/01.CIR.0000141730.65972.95
28. Marschang P, Sandhofer A, Ritsch A, Fi͉er I, Kvas E, Patsch JR, Plasma cholesteryl ester transfer protein concentrations predict cardiovascular events in patients with coronary artery disease treated with pravastatin. J Intern Med 2006 260 151 159. doi: 10.1111/j.1365-2796.2006.01674.x
29. Borggreve SE, Hillege HL, Dallinga-Thie GM, de Jong PE, Wolffenbuttel BH, Grobbee DE, van Tol A, Dullaart RP, PREVEND Study Group High plasma cholesteryl ester transfer protein levels may favour reduced incidence of cardiovascular events in men with low triglycerides. Eur Heart J 2007 28 1012 1018. doi: 10.1093/eurheartj/ehm062
30. Vasan RS, Pencina MJ, Robins SJ, Zachariah JP, Kaur G, D'Agostino RB, Ordovas JM, Association of circulating cholesteryl ester transfer protein activity with incidence of cardiovascular disease in the community. Circulation 2009 120 2414 2420. doi: 10.1161/CIRCULATIONAHA.109.872705
31. Robins SJ, Lyass A, Brocia RW, Massaro JM, Vasan RS, Plasma lipid transfer proteins and cardiovascular disease: the Framingham Heart Study. Atherosclerosis 2013 228 230 236. doi: 10.1016/j.atherosclerosis.2013.01.046
32. Ritsch A, Scharnagl H, Eller P, Tancevski I, Duwensee K, Demetz E, Sandhofer A, Boehm BO, Winkelmann BR, Patsch JR, März W, Cholesteryl ester transfer protein and mortality in patients undergoing coronary angiography: the Ludwigshafen Risk and Cardiovascular Health study. Circulation 2010 121 366 374. doi: 10.1161/CIRCULATIONAHA.109.875013
33. Duwensee K, Breitling LP, Tancevski I, Rothenbacher D, Demetz E, Patsch JR, Ritsch A, Eller P, Brenner H, Cholesteryl ester transfer protein in patients with coronary heart disease. Eur J Clin Invest 2010 40 616 622. doi: 10.1111/j.1365-2362.2010.02313.x
34. Khera AV, Wolfe ML, Cannon CP, Qin J, Rader DJ, On-statin cholesteryl ester transfer protein mass and risk of recurrent coronary events (from the pravastatin or atorvastatin evaluation and infection therapy-Thrombolysis in myocardial infarction 22 [PROVE IT-TIMI 22] study). Am J Cardiol 2010 106 451 456. doi: 10.1016/j.amjcard.2010.03.057
35. Seiler S, Schlitt A, Jiang XC, Ulrich C, Blankenberg S, Lackner KJ, Girndt M, Werdan K, Buerke M, Fliser D, Heine GH, Cholesteryl ester transfer protein activity and cardiovascular events in patients with chronic kidney disease stage V. Nephrol Dial Transplant 2008 23 3599 3604. doi: 10.1093/ndt/gfn296
36. Tatò F, Vega GL, Tall AR, Grundy SM, Relation between cholesterol ester transfer protein activities and lipoprotein cholesterol in patients with hypercholesterolemia and combined hyperlipidemia. Arterioscler Thromb Vasc Biol 1995 15 112 120
37. Dullaart RP, de Vries R, Kwakernaak AJ, Perton F, Dallinga-Thie GM, Increased large VLDL particles confer elevated cholesteryl ester transfer in diabetes. Eur J Clin Invest 2015 45 36 44. doi: 10.1111/eci.12377
38. van Venrooij FV, Stolk RP, Banga JD, Sijmonsma TP, van Tol A, Erkelens DW, Dallinga-Thie GM, DALI Study Group Common cholesteryl ester transfer protein gene polymorphisms and the effect of atorvastatin therapy in type 2 diabetes. Diabetes Care 2003 26 1216 1223
39. Bellanger N, Julia Z, Villard EF, El Khoury P, Duchene E, Chapman MJ, Fournier N, Le Goff W, Guerin M, Functionality of postprandial larger HDL2 particles is enhanced following CETP inhibition therapy. Atherosclerosis 2012 221 160 168. doi: 10.1016/j.atherosclerosis.2011.12.027
40. Ray KK, Ditmarsch M, Kallend D, Niesor EJ, Suchankova G, Upmanyu R, Anzures-Cabrera J, Lehnert V, Pauly-Evers M, Holme I, Štásek J, van Hessen MW, Jones P, dal-ACUTE Investigators The effect of cholesteryl ester transfer protein inhibition on lipids, lipoproteins, and markers of HDL function after an acute coronary syndrome: the dal-ACUTE randomized trial. Eur Heart J 2014 35 1792 1800. doi: 10.1093/eurheartj/ehu105
41. Yvan-Charvet L, Kling J, Pagler T, Li H, Hubbard B, Fisher T, Sparrow CP, Taggart AK, Tall AR, Cholesterol efflux potential and antiinflammatory properties of high-density lipoprotein after treatment with niacin or anacetrapib. Arterioscler Thromb Vasc Biol 2010 30 1430 1438. doi: 10.1161/ATVBAHA.110.207142
42. Wang SP, Daniels E, Chen Y, Castro-Perez J, Zhou H, Akinsanya KO, Previs SF, Roddy TP, Johns DG, In vivo effects of anacetrapib on preβ HDL: improvement in HDL remodeling without effects on cholesterol absorption. J Lipid Res 2013 54 2858 2865. doi: 10.1194/jlr.M041541
43. Nicholls SJ, Brewer HB, Kastelein JJ, Krueger KA, Wang MD, Shao M, Hu B, McErlean E, Nissen SE, Effects of the CETP inhibitor evacetrapib administered as monotherapy or in combination with statins on HDL and LDL cholesterol: a randomized controlled trial. JAMA 2011 306 2099 2109. doi: 10.1001/jama.2011.1649
44. Barter PJ, Caulfield M, Eriksson M, Grundy SM, Kastelein JJ, Komajda M, Lopez-Sendon J, Mosca L, Tardif JC, Waters DD, Shear CL, Revkin JH, Buhr KA, Fisher MR, Tall AR, Brewer B, ILLUMINATE Investigators Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med 2007 357 2109 2122. doi: 10.1056/NEJMoa0706628
45. Schwartz GG, Olsson AG, Abt M, Ballantyne CM, Barter PJ, Brumm J, Chaitman BR, Holme IM, Kallend D, Leiter LA, Leitersdorf E, McMurray JJ, Mundl H, Nicholls SJ, Shah PK, Tardif JC, Wright RS, dal-OUTCOMES Investigators Effects of dalcetrapib in patients with a recent acute coronary syndrome. N Engl J Med 2012 367 2089 2099. doi: 10.1056/NEJMoa1206797
46. Schaefer EJ, Asztalos BF, Increasing high-density lipoprotein cholesterol, inhibition of cholesteryl ester transfer protein, and heart disease risk reduction. Am J Cardiol 2007 100 11 A n25-n31. doi: 10.1016/j.amjcard.2007.08.010
47. Kastelein JJ, van Leuven SI, Burgess L, Evans GW, Kuivenhoven JA, Barter PJ, Revkin JH, Grobbee DE, Riley WA, Shear CL, Duggan WT, Bots ML, RADIANCE 1 Investigators Effect of torcetrapib on carotid atherosclerosis in familial hypercholesterolemia. N Engl J Med 2007 356 1620 1630. doi: 10.1056/NEJMoa071359
48. Bots ML, Visseren FL, Evans GW, Riley WA, Revkin JH, Tegeler CH, Shear CL, Duggan WT, Vicari RM, Grobbee DE, Kastelein JJ, RADIANCE 2 Investigators Torcetrapib and carotid intima-media thickness in mixed dyslipidaemia (RADIANCE 2 study): a randomised, double-blind trial. Lancet 2007 370 153 160. doi: 10.1016/S0140-6736(07)61088-5
49. Nissen SE, Tardif JC, Nicholls SJ, Revkin JH, Shear CL, Duggan WT, Ruzyllo W, Bachinsky WB, Lasala GP, Lasala GP, Tuzcu EM, ILLUSTRATE Investigators Effect of torcetrapib on the progression of coronary atherosclerosis. N Engl J Med 2007 356 1304 1316. doi: 10.1056/NEJMoa070635
50. Fayad ZA, Mani V, Woodward M, Kallend D, Abt M, Burgess T, Fuster V, Ballantyne CM, Stein EA, Tardif JC, Rudd JH, Farkouh ME, Tawakol A, dal-PLAQUE Investigators Safety and efficacy of dalcetrapib on atherosclerotic disease using novel non-invasive multimodality imaging (dal-PLAQUE): a randomised clinical trial. Lancet 2011 378 1547 1559. doi: 10.1016/S0140-6736(11)61383-4
51. Lüscher TF, Taddei S, Kaski JC, Jukema JW, Kallend D, Münzel T, Kastelein JJ, Deanfield JE, dal-VESSEL Investigators Vascular effects and safety of dalcetrapib in patients with or at risk of coronary heart disease: the dal-VESSEL randomized clinical trial. Eur Heart J 2012 33 857 865. doi: 10.1093/eurheartj/ehs019